ICON Public Limited (NASDAQ:ICLR) Receives $321.64 Average PT from Brokerages

ICON Public Limited (NASDAQ:ICLR) has earned an average recommendation of “Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $327.50.

Several research firms have weighed in on ICLR. Evercore ISI reduced their target price on ICON Public from $350.00 to $330.00 and set an “outperform” rating on the stock in a report on Friday. Barclays increased their target price on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. TD Cowen raised their target price on shares of ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a report on Friday. Robert W. Baird upped their price target on shares of ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a report on Friday. Finally, Mizuho restated a “buy” rating and set a $346.00 price objective on shares of ICON Public in a report on Thursday, April 4th.

ICON Public Stock Down 1.4 %

NASDAQ ICLR opened at $304.14 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21. ICON Public has a 52 week low of $181.92 and a 52 week high of $344.77. The stock has a market capitalization of $25.09 billion, a P/E ratio of 37.00, a price-to-earnings-growth ratio of 1.45 and a beta of 1.15. The stock has a fifty day moving average of $319.19 and a 200-day moving average of $283.75.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. On average, equities research analysts forecast that ICON Public will post 14.4 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Steph & Co. lifted its holdings in shares of ICON Public by 4.6% during the third quarter. Steph & Co. now owns 1,670 shares of the medical research company’s stock worth $411,000 after buying an additional 73 shares in the last quarter. Whittier Trust Co. grew its stake in shares of ICON Public by 58.6% in the third quarter. Whittier Trust Co. now owns 2,544 shares of the medical research company’s stock valued at $626,000 after acquiring an additional 940 shares in the last quarter. Kornitzer Capital Management Inc. KS increased its position in ICON Public by 17.5% during the third quarter. Kornitzer Capital Management Inc. KS now owns 49,660 shares of the medical research company’s stock worth $12,229,000 after acquiring an additional 7,385 shares during the period. NBC Securities Inc. acquired a new stake in ICON Public in the 3rd quarter worth about $174,000. Finally, Motco raised its stake in ICON Public by 766.4% in the 3rd quarter. Motco now owns 1,291 shares of the medical research company’s stock worth $318,000 after purchasing an additional 1,142 shares in the last quarter. 95.61% of the stock is owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.